| Literature DB >> 35265977 |
Ee Von Woon1,2, Orene Greer1, Nishel Shah1, Dimitrios Nikolaou2, Mark Johnson1, Victoria Male1.
Abstract
BACKGROUND: Uterine natural killer cells (uNK) are the most abundant lymphocytes found in the decidua during implantation and in first trimester pregnancy. They are important for early placental development, especially trophoblast invasion and transformation of the spiral arteries. However, inappropriate uNK function has been implicated in reproductive failure, such as recurrent miscarriage (RM) or recurrent implantation failure (RIF). Previous studies have mainly focussed on peripheral NK cells (pNK), despite the well-documented differences in pNK and uNK phenotype and function. In recent years, there has been an explosion of studies conducted on uNK, providing a more suitable representation of the immune environment at the maternal-foetal interface. Here, we summarize the evidence from studies published on uNK in women with RM/RIF compared with controls. OBJECTIVE AND RATIONALE: The objectives of this systematic review and meta-analysis are to evaluate: differences in uNK level in women with RM/RIF compared with controls; pregnancy outcome in women with RM/RIF stratified by high and normal uNK levels; correlation between uNK and pNK in women with RM/RIF; and differences in uNK activity in women with RM/RIF compared with controls. SEARCHEntities:
Keywords: assisted reproduction; endometrium; flow cytometry; immunohistochemistry; immunology; natural killer cells; recurrent implantation failure; recurrent miscarriage; reproductive immunology
Mesh:
Substances:
Year: 2022 PMID: 35265977 PMCID: PMC9247428 DOI: 10.1093/humupd/dmac006
Source DB: PubMed Journal: Hum Reprod Update ISSN: 1355-4786 Impact factor: 17.179
Figure 1.Preferred reporting items for systematic reviews and meta-analyses diagram.
Characteristics of studies included in meta-analyses
| Study ID | Aim(s) of the study | Study design and cohort | Type and timing of sample | Method of analysis, uNK phenotype and unit of measurement | uNK reference range | Data extracted |
|---|---|---|---|---|---|---|
|
| To examine the differences in TCR expression in peripheral blood and intra-decidual T cells and in NK cell activity in normal pregnancy, anembryonic pregnancy and recurrent spontaneous abortion. | Case control study comparing women with ≥ 3 uRM (n=10) and fertile controls (n=21) | Decidual tissue; Between 6-10 weeks GA | FC; CD45+/CD14-/CD56+ or CD16+; Percentage of CD45+CD14- lymphocytes | N/A | uNK level and activity |
|
| To clarify the immunologic role of endometrial leycocytes in uRM by analysis of T, B, NK cells and monocytes. | Case control study comparing women with ≥ 3 uRM (n=20) and fertile controls (n=15) | Endometrial tissue; Day 18 to 25 of menstrual cycle | FC; CD3-CD45+CD56+CD16+ and CD3-CD45+CD56+CD16-; Percentage of CD3-CD45+ lymphocytes | N/A | uNK level, pregnancy outcome (narrative only) |
|
| To investigate localisation of bcl-2 at the maternal-fetal interface in first trimester and to determine if this may disturb early stages of pregnancy failure | Case control study comparing women with ≥ 3 uRM (n=23) and fertile controls (n=22) | Decidual tissue; Between 7-14 weeks GA | IHC; CD56; Percentage of stained nucleated cells | N/A | uNK level and activity |
|
| To evaluate maternal pNK and dNK in RM with normal chromosomal content | Case control study comparing women with ≥ 3 uRM (n=9) and controls (n=15) | Decidual tissue; Between 5-11 weeks GA | FC; CD45+/CD14-/CD56+ or CD16+ or CD56+/CD16- or CD56+/CD16-/CD3-; Percentage of CD45+CD14- lymphocytes | N/A | uNK level |
|
| To quantify the endometrial CD56+ NK cell population in women with a history of recurrent miscarriage | Case control study comparing women with ≥ 3 uRM (n=29) and fertile controls (n=10) | Endometrial tissue; Between day 7 to 10 after urine LH surge | IHC; CD56+; Absolute number per 10hpf | N/A | uNK level |
|
| To investigate the immunophenotypic profile of the endometrium of women suffering recurrent pregnancy loss | Case control study comparing women with ≥ 3 uRM (n=22) and fertile controls (n=9) | Endometrial tissue; Mid-luteal on day 21 by LMP confirmed by serum oestrogen and progesterone and histological dating (excluded if not day 19-22) | IHC; CD16, CD56, CD57 and CD69; Percentage of total cells per 10 hpf | N/A | uNK level |
|
| To determine whether decidual leukocyte subpopulations and their associated activation markers were different between women having RM of either a trisomy 16 compared with a chromosomally normal male conceptus and compared with women having elective pregnancy termination. | Case control study comparing women with ≥ 3 uRM (n=17) and fertile controls (n=20) | Decidual tissue; Between 6-10 weeks GA | IHC; CD56+ Ratio of CD45+ cells and absolute number per 10 hpf | N/A | uNK level |
|
| To evaluate the ability of immunophenotypes of endometrial leukocytes from patients with histories of recurrent abortion to predict outcome of subsequent pregnancy. | Case control study comparing women with ≥ 2 uRM (n=17) and controls from male infertility (n=15) | Endometrial tissue; Between day 5 to 8 after urine LH surge | IHC; CD45+, CD56+, CD16+; Percentage of CD45+ cells and absolute number per 10 hpf | N/A | uNK level |
|
| To investigate the endometrial immunohistochemical staining of interleukin (IL)-12 and IL-18 and to quantify the CD56 bright natural killer (NK) cells in relation to Doppler vascular disorder | Case control study comparing women with ≥ 3 RIF (n=35) and fertile controls (n=12) | Endometrial tissue; On Day 20 based on oestrogen-progestin treatment (in patient group and 6 controls) or urinary LH (in 5 controls) | IHC; CD56+; Absolute number per 3 of 100x field | N/A | uNK level and activity |
|
| To assess the NK cell and NKT cell populations and cytokine expression of T-helper cells in the endometrium of women who suffered from uR | Case control study comparing women with ≥ 3 uRM (n=20) and fertile controls (n=17) | Endometrial tissue; Between day 5 to 9 post ovulation as determined by basal body temperature | FC; CD56+, CD56+CD16+ and CD56+CD16-; Percentage over total lymphocytes | N/A | uNK level |
|
| To investigate whether the number of pre-pregnancy endometrial CD56+ cells in women with uRM is able to predict outcome in a subsequent pregnancy. | Case control comparing women with ≥ 3 uRM (n=87) and controls (n=10) | Endometrial tissue; Between day 7 to 10 after urine LH surge | IHC; CD56+; Absolute number in 10 hpf | >13.8% as abnormally high (90th percentile of control group) | uNK level and pregnancy outcome |
|
| To understand osteopontin expression and regulation in decidua,osteopontin expression was examined in human first-trimester decidua from RM patients | Case control comparing women with uRM (n=22) and controls (n=25) | Decidual tissue; Between 4-9 weeks GA | IHC; CD56+ Staining intensity and absolute number | N/A | uNK staining intensity and activity |
|
| To compare CD57+ NK cells in normal pregnancies and different types of early pregnancy failure | Case control study comparing women with ≥ 3 uRM (n=23) and controls (n=23) | Decidual tissue; Between 6-12 weeks GA, obtaned within 1 hour of diagnosis of miscarriage by USS | IHC; CD57+; Absolute number per cm2 | N/A | uNK level |
|
| To address the question of possibly altered endometrial immune-cell concentrations | Case control study comparing women with ≥ 2 uRM (n=25) and controls (n=10) | Endometrial tissue; Between day 8 to 9 after urine LH surge | IHC; CD56+; Staining intensity (0-3) | N/A | uNK staining intensity |
|
| To investigate whether or not the number of pre-pregnancy endometrial CD56 cells in women with unexplained RM is able to predict outcome in a subsequent pregnancy. | Case control study comparing women with RIF after ≥ IVF cycles or ≥ 2 IVF plus 2 frozen ET cycles (n=40) and controls (n=15) | Endometrial tissue; Between day 7 to 9 after urine LH surge | IHC; CD56+ and CD16+; Percentage of total stromal cells | >13.8% as abnormally high (90th percentile of control group) | uNK level and pregnancy outcome |
|
| To compare numbers of CD56+ cells in peripheral blood and endometrium | Case control study comparing eNK and pNK in women with ≥ 3 uRM (n=25); Separate analysis of IHC vs FC of CD56+ eNK in fertile controls (n=20) | Endometrial tissue; Between day 7 to 9 after urine LH surge | IHC; CD56+; Percentage of total stromal cells | N/A | uNK and pNK correlation |
|
| To determine if there is a functional difference between the uNK in women with UI versus those with uRM, the percentage of NK cells (CD56+) as well as NK cell cytotoxic(CD16) and inhibitory (NKG2a) receptors were compared to controls | Case control study comparing women with uRM (n=24) and fertile controls (n=10) | Endometrial tissue; Mid-secretory phase | IHC; CD56+; Percentage of stromal cells for uNK level | N/A | uNK level only |
|
| To define the candidates for this test and to find the best methodology and to establish a reasonable cut-off value for normal uNK and to check if pNK correlate with uNK | Case control study comparing women with ≥ 3 RIF (idiopathic, n=32; other causes, n=41) and fertile controls (n=17) | Endometrial tissue; between Day 19 to 23 based on LMP in women with regular periods or Day 5 to 9 after positive urine LH | For uNK: IHC, CD56+, Percentage of total stromal cells and absolute number per 10 hpf For pNK: FC, CD3-CD56+ or CD16+, percentage of total lymphocytes | For uNK: Low (<150 cells/10 hpf), Moderate (150-250 cells/10hpf), Intense (>250 cells/hpf); For pNK: High (>12% of total lymphocyte) | uNK level, correlation pNK and uNK; uNK activity |
|
| To compare the expres-sion of CD56, CD16, and NKp46 in the eutopic endometrium from women with uRM or UI to fertile patients and correlate this with the presence or the absence of endometriosis | Case control study comparing women with ≥ 2 uRM patients (n=13) and fertile controls (n=10) | Endometrial tissue; between Day 7 to 9 post urine LH surge | IHC; CD56+ and CD16+; Percentage to total endometrial stromal cells | N/A | uNK level |
|
| To determine uterine and systemic values of CD16+/- NK cells, IL-6, and VEGF during the implantation window and to establish a correlation between the number and phenotype of endometrial versus peripheral blood NK cells in unexplained infertility patients with RIF compared to fertile women. | Case control study comparing women with unexplained infertility and ≥ 2 failed IVF versus fertile controls | Endometrial tissue; between Day 5 to 9 after ovulation confirmed by USS | FC; CD56+CD9+ and CD56+CD16+CD9+; Percentage over 1x105 endometrial cells | N/A | uNK level, correlation and activity |
|
| To study function of dNK and successful pregnancy and examine NK cell subsets, distribution and cytokine secretion profiles. | Prospective case control comparing uRM and controls | Decidual tissue; Between 6-12 weeks confirmed by USS | FC, CD3- /CD56+; Percentage NOS | N/A | uNK level and activity |
|
| To examine the hypothesis that prognostic value of uNK measurement on pregnancy outcome is improved when combined with histological dating | Retrospective study of women with ≥ 3 uRM and ≥ 3 RIF | Endometrial tissue; between Day 7 to 9 post urine LH surge | IHC; CD56+; Percentage of total stromal cells | >13.9% as abnormally high | Pregnancy outcome |
|
| To investigate the relationship between expression of KIR on dNK and gestational age in this relationship | Case control study comparing women with ≥ 2 uRM patients (n=30) and fertile controls (n=30) | Decidual tissue; At first trimester, gestational age dated by LMP | FC; CD56+, CD56+/CD16-; CD56+/CD16+, CD56-/CD16+, CD56-CD16-; Percentage of total leucocytes | N/A | uNK level and activity |
|
| To compare NK cell subsets in menstrual and peripheral blood of RM patients and fertile women | Case control study comparing women with ≥ 2 uRM patients (n=14) and fertile controls (n=9) | Menstrual blood | FC; CD3-CD56+CD16+, CD3-CD56+CD16+ | N/A | uNK level and activity |
|
| To detail the mechanisms of the interaction of dNK and trophoblast cells during normal and pathological early pregnancy. | Case control study comparing women with ≥ 2 uRM patients (n=26) and controls (n=37) | Decidual tissue; Between 7-11 weeks GA | FC; CD45+/CD14-/CD56+; Percentage of CD45+CD14- lymphocytes | N/A | uNK level and activity |
|
| To measure the frequency of T and NK cells in uRM patients and normal pregnant women by FC. | Case control study comparing women with uRM patients (n=30) and controls (n=30) | Decidual tissue; In first trimester pregnancy | FC; CD16+CD56+; Percentage of total lymphocytes | N/A | uNK level |
|
| To evaluate the remodelling of decidual spiral arteries in the early human deciduas in women with uRM and their possible relationship with the immunoexpressive behaviour and ultrastructural properties of dNKC | Case control study comparing women with ≥ 3 uRM (n=40) and fertile controls (n=30) | Decidual tissue; Between 6-10 weeks GA | IHC; Absolute number of cells/mm2 per 5 hpf | N/A | uNK level and activity |
|
| To determine role of HLA-G, CD8, CD16, CD56, IFN-g and TNF-a for RM in feto–maternal interface. | Case control study comparing women with ≥ 2 uRM patients (n=10) and controls (n=11) | Decidual tissue; Between 6-11 weeks GA for RM and <10 weeks GA for controls; | Western blot; CD56+ and CD16+ Protein expression normalised to B-Actin band intensities | N/A | uNK level |
|
| To identify subpopulations of decidual lymphocytes of RM by IHC study of decidua | Case control study comparing women with ≥ 3 uRM patients (n=30) and controls (n=30) | Decidual tissue; at time of miscarriage or TOP | IHC; CD56+ or CD57+ Absolute number of cells per 10 hpf | N/A | uNK level |
|
| To compare the uNK percentage in women with recurrent reproductive failure and fertile controls | Case control study comparing women with ≥ 3 uRM patients (n=97), RIF patients after ≥ 3 fresh /frozen cycle embryo transfer (n=34) and controls (n=84) | Endometrial tissue; Day 7 post urine LH surge | IHC; CD56+; Percentage of stromal cells per 10 hpf | N/A | uNK level |
|
| To define a more precise parameter for a better understanding of NK cells and its relation with Tregs in women with RIF. | Case control study comparing women with ≥ 2 RIF (n=32) and controls with male infertility (n=23) | Endometrial tissue; At Day 7 post urine LH surge | IHC; CD56+ and CD57+; Percentage of total stromal cells | N/A | uNK level and activity |
|
| To analyze uNK cell concentration in the endometrium of idiopathic RM patients and fertile controls to establish possible cut-off values. | Case control study comparing women with ≥ 3 uRM (n=58) and fertile controls (n=217) | Endometrial tissue; Day 7-10 post urine LH surge, confirmed by endometrial glands and stroma evaluation | IHC; CD56+; Absolute number cells/mm2 | N/A | uNK level |
|
| To define the decidual immune cells and to simultaneously detect changes in the Th1/Th2 and decidual NK1 /decidual NK2 ratios of the decidual tissues using FC. | Case control study comparing women with ≥ 2 uRM (n=20) and fertile controls (n=20) | Decidual sample; 1st trimester (6-11 weeks), obtained by ERPC within 3 days of fetal loss in uRM or 7 days in controls | FC; CD3-CD56+/CD56brightCD16- Percentage of parental population (i.e. CD3-CD56+) | N/A | uNK level and activity |
|
| To confirm that miR-133a negatively regulates HLA-G expression to influence dNK function via KIR2DL4 in RM patients. | Case control study comparing women with R (n=11) and fertile controls (n=12) | Decidual sample; At 7 to 12 weeks GA | FC; CD45+/CD3-/CD56+/CD56brightCD16-; Percentage of CD45+/CD3- lymphocytes | N/A | uNK level and activity |
|
| To investigate a possible role of uNK cells in vascular development and describe characteristics of endometrial vascular patterns in women with RPL | Case control study comparing women with uRM (n=15) and controls (n=7) | Endometrial tissue; Day 7-9 post urine LH surge | IHC; CD56+ and CD16+; Absolute number of positive cells per mm2 | N/A | uNK level and activity |
|
| To investigate whether Th, Tc, NK and NKT cells population and cytokine expression is associated with msicarriages with abnormal chromosome karyotype | Case control study comparing women with uRM (n=10) and controls (n=21) | Decidual sample; At 6-10 weeks GA | FC; CD3-CD56brightCD16-; Percentage of lymphocytes NOS | N/A | uNK level and activity |
|
| To determine whether endometrial immune profiles in adverse reproductive outcomes such as RIF and RM differ from each other and male-factor controls | Case control study comparing women with ≥ 2 RIF (n=181),≥ 2 RM (n=155) and male factor infertility controls (n=35) | Endometrial tissue; Day 21 to 24 menstrual cycle after HRT (5 days of vaginal progesterone) | FC; Total CD56 as percentage over total endometrial cells and CD45+CD3-CD5-CD56brightCD16- as percentage over CD45+ leucocytes | N/A | uNK level only |
|
| To describe a novel technique for calculation of local endometrial lymphocyte concentrations, and to compare results between RIF and RM with male-factor controls. | Case control study comparing women with ≥ 2 RIF (n=149),≥ 2 RM (n=121) and male factor infertility controls (n=29) | Endometrial tissue; Day 21 to 24 menstrual cycle after HRT (5 days of vaginal progesterone) | FC; Median uNK concentration (cells/mg) | >90th centile versus 25th to 75th centile | Pregnancy outcome only |
|
| To explore expression of CD82 on dNK and role of trophoblast cells, CD29 and CD82 on adhesive ability of dNK to DSC in vitro | Case control study comparing women with ≥ 2 uRM (n=8) and controls (n=45) | Decidual tissue; 1st trimester (6-8 weeks) | FC; CD45+CD3-CD56bright or CD56dim; Percentage of over total CD56 | N/A | uNK level and activity |
|
| To localize IDO in the endometrium, investigate IDO expression between patients associated with RM andhealthy fertile controls, and undertake a correlation study on IDO and other immune cells. | Case control study comparing women with ≥ 2 uRM (n=58) and male factor infertility controls (n=49) | Endometrial tissue; At mid luteal phase confirmed by H&E staining | IHC; CD56+; Percentage of total endometrial cells | N/A | uNK level and activity |
|
| To investigate if dysregulation of uNK, FoxP3 cells, PGRMC1 expression and if crosstalk between these factors play a role in RM. | Case control study comparing women with ≥ 2 uRM (n=39) and controls (n=63) | Endometrial tissue; Day 7 to 9 after ovulation confirmed by USS | IHC; CD56+; Absolute number of cells/mm2 per 10hpf | N/A | uNK level and activity |
|
| To investigate the density and clustering of four different immune cells simultaneously in precisely timed endometrial specimens and compared the results between women with RM and fertile controls subjects | Case control study comparing women with ≥ 3 uRM (n=39) and fertile controls (n=63) | Endometrial tissue; Day 7 after LH surge | IHC; CD56+; Percentage of total stromal cells | N/A | uNK level |
|
| To evaluate whether there was a significant difference in the number of endometrial CD56+ NK between women with RIF and women who had a live birth. | Case control study comparing women with ≥ 3 RIF (n=25) and fertile controls (n=25) | Endometrial tissue; Day 21 to 24 based on LMP | IHC; CD56+; Absolute number of cells/mm2 | N/A | uNK level |
|
| To investigate if frequency of euploid miscarriage is increased in women with high uterine CD56+ cell density | Prospective cohort study comparing women with ≥ 3 uRM (n=42) and controls (n=12) from previous study | Endometrial tissue; Day 7 after LH surge | IHC; CD56+; Percentage of CD56+ uNK in | > 4.5% as abnormally high | Pregnancy outcome only |
Studies with duplicate data, different data were extracted from each study for separate meta-analyses;
uNK level data not extracted as controls from previous study. uRM, unexplained recurrent miscarriage; RIF, recurrent implantation failure; IVF, in vitro fertilization; GA, gestational age; ERPC, evacuation of retained products of conception; LMP, last menstrual period; USS, ultrasound; LH, luteinizing hormone; HRT, hormone replacement therapy; IHC, immunohistochemistry; FC, flow cytometry; hpf, high power field; H&E, haematoxylin and eosin; NK, Natural Killer; uNK, uterine Natural Killer cells; pNK, peripheral Natural Killer cells; dNK, decidual Natural Killer cells; NKT, Natural Killer-T cells; Th, T helper cells; Treg, T regulatory cells; TCR, T-cell receptor; IL, interleukin; bcl-2, B-cell leukaemia/lymphoma 2; PGRMC1, progesterone receptor membrane component 1; IDO, indoleamine 2,3 dioxygenase
Risk of bias in non-randomized studies of interventions of uNK level/activity in women with RM/RIF compared with healthy controls.
| Study ID | Pre-intervention | At intervention | Post-intervention | Total score | ||||
|---|---|---|---|---|---|---|---|---|
| Confounding bias | Selection bias | Classification bias | Deviation bias | Missing data bias | Measurement of outcome bias | Selective reporting bias | Overall risk of bias judgement | |
|
| Serious | Low | Low | Low | Serious | Moderate | Low | Serious |
|
| Moderate | Low | Low | Low | Serious | Moderate | Moderate | Serious |
|
| Serious | Low | Low | Low | Low | Moderate | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Moderate | Moderate |
|
| Serious | Low | Low | Low | Low | Low | Moderate | Serious |
|
| Serious | Moderate | Low | Low | Low | Serious | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Low | Low | Moderate |
|
| Serious | Low | Low | Low | Low | Moderate | Low | Serious |
|
| Serious | Serious | Low | Low | Moderate | Low | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Serious | Low | Low | Low | Moderate | Moderate | Moderate | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Serious | Low | Low | Low | Low | Low | Low | Serious |
|
| Serious | Low | Moderate | Low | Serious | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Low | Low | Serious |
|
| Serious | Low | Moderate | Low | Moderate | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Moderate | Serious | Serious |
|
| Moderate | Low | Low | Low | Moderate | Moderate | Low | Moderate |
|
| Serious | Low | Low | Low | Low | Low | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| No info | Low | Low | Low | No info | Low | Low | No info |
|
| Moderate | Low | Low | Low | Low | Moderate | Moderate | Moderate |
|
| Serious | Low | Low | Low | Low | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Critical | Low | Low | Critical |
|
| Moderate | Moderate | Low | Low | Low | Low | Serious | Serious |
|
| Serious | Low | Low | Low | Serious | Low | Low | Serious |
|
| Serious | Low | Low | Low | Serious | Low | Moderate | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Moderate | Moderate |
|
| Serious | Low | Low | Low | Low | Moderate | Moderate | Serious |
|
| Moderate | Low | Low | Low | Moderate | Moderate | Moderate | Moderate |
|
| Moderate | Low | Low | Low | Low | Low | Low | Moderate |
|
| Serious | Low | Moderate | Low | Low | Low | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Serious | Low | Low | Low | Low | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Low | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Serious | Low | Low | Low | Low | Moderate | Moderate | Serious |
|
| Moderate | Low | Moderate | Low | Moderate | Moderate | Moderate | Moderate |
|
| Moderate | Low | Low | Low | Low | Moderate | Moderate | Moderate |
|
| Serious | Low | Moderate | Low | Low | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Low | Moderate | Serious |
|
| Moderate | Low | Serious | Low | Low | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Low | Moderate | Serious |
|
| Serious | Low | Low | Low | Low | Moderate | Moderate | Serious |
|
| Moderate | Low | Low | Low | Serious | Low | Low | Serious |
|
| Serious | No information | Serious | Low | Moderate | Moderate | Low | Serious |
|
| Moderate | Low | Low | Low | Serious | Low | Low | Serious |
|
| Serious | Low | Low | Low | Serious | Moderate | Serious | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Moderate | Moderate |
|
| Serious | Low | Moderate | Low | Low | Moderate | Low | Serious |
|
| Serious | Low | Low | Low | Low | Moderate | Moderate | Serious |
|
| Serious | Low | Low | Low | Low | Low | Low | Serious |
|
| Moderate | Low | Low | Low | Low | Serious | Serious | Serious |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Moderate |
|
| Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
RIF, recurrent implantation failure; RM, recurrent miscarriage.
Figure 2.Funnel plot of all the studies included in the meta-analyses of uterine natural killer level.
Figure 3.Level of uNK in women with recurrent miscarriage compared with controls. (A) Total CD56+ uNK. (B) CD56+CD16− uNK. (C) CD56+CD16+ uNK. (D) CD57+ uNK. RM, recurrent miscarriage; uNK, uterine natural killer cells.
Figure 4.Subgroup analyses of of uNK level in women with recurrent miscarriage compared with controls. (A) Endometrium CD56+ uNK. (B) Endometrium CD56+CD16− uNK. (C) Decidua CD56+ uNK. (D) Decidua CD56+CD16− uNK.
Figure 5.uNK level in women with recurrent implantation failure compared with controls. (A) Total CD56+ uNK in endometrium. (B) Sensitivity analysis of CD56+ uNK level excluding male factor infertility. (C) Individual study comparison of CD56+CD16+, CD57+ and CD56+CD16−. RIF, recurrent implantation failure.
Figure 6.Subgroup analyses of uNK level in women with RIF compared with controls. (A) By method of analysis. (B) By unit of measurement.
Figure 7.Meta-analysis by pregnancy outcome. (A) Livebirth outcome in women with RM/RIF and normal compared with high uNK level. (B) Individual study comparison of clinical pregnancy rate in women with RM/RIF and normal compared with high uNK level. (C) uNK level in women with RM/RIF with subsequent livebirth compared with miscarriage. Marron 2019b refers to Marron and Harrity, 2019
Figure 8.Correlation between peripheral NK and uNK. (A) Meta-analysis of coefficient correlation of CD56+CD16− pNK and CD56 uNK. (B) Meta-analysis of coefficient correlation of CD56+CD16+ pNK and CD56+ uNK. pNK, peripheral natural killer cells.
Uterine NK cell activity, by NK cell regulation and receptors.
| Author/Year | Study design | Study groups and sample number | Tissue analysed | Method of analysis | Outcome measure, e.g. receptor expression | Direction of effect in RM/RIF patients |
|---|---|---|---|---|---|---|
|
| Prospective case control |
71 uRM (n = 71) vs patients and STOP for healthy controls (n = 20) | Decidual samples at ERPC (uRM patients) and STOP for healthy controls (all <12/40) | IHC/histology |
30% of women with RM demonstrated increased NK cell infiltrates in maternal decidua at the implantation site. No correlation between increased NK cell infiltrates at the implantation site with (i) inadequate depth of invasion (ii) inadequate number of intermediate trophoblast | Qualitative analysis |
|
| ||||||
|
| Prospective Case Control | RM (n = 9); 2 controls (n = 11) | Decidual tissue at time of ERPC or TOP; 2 hysterectomy specimens | IHC | Expression of | |
| • CD56 | ↑ | |||||
| • CD16 | ↑ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 10) vs controls (n = 23) | FC; semi-quantitative RT-PCR | uNK expression of | ||
| • KIR2DL4 | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 22) vs controls (n = 25) | Decidual tissue at time of miscarriage or TOP | RT-PCR; IHC | Expression of | |
| • Osteopontin | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 32) vs controls (n-35) | Decidual samples at time of miscarriage/TOP | PCR; western blot | TLR3 expression | |
| • mRNA (median) | ↑ | |||||
| • Protein (ratio:β-actin) | ↑ | |||||
|
| ||||||
|
| Prospective observational |
RM (n = 25) vs controls (n = 285) | Decidual samples at time of miscarriage/TOP | FC; ELISA | • CD27+ NK cells: Th17 cell ratio | ↓ |
|
| ||||||
|
| Prospective case control |
RM (n = 15) vs controls (n = 15) | Menstrual blood sample on Day 2 of menstruation | FC | Expression of | |
| • CCR7 | ↑ | |||||
| on | ||||||
| CD56+CD16+ and CD56+CD16− | ||||||
| • CD45RO | ↓ | |||||
| on CD56+CD3− | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 26) vs Controls (n = 37) | Decidual samples at time of miscarriage/TOP | FC; PCR | Expression of: | |
| • CD56+CD161+ | ↑ | |||||
| • CD56+NKG2A+ | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 30) vs Controls (n = 30) | Decidual samples at time of miscarriage/TOP | FC | CD56+/CD16−/CD158a+ cells | |
| • KIR2DL1/S1 | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 11) vs controls (n = 12) | Decidual samples at time of miscarriage/TOP | FC, PCR, Matrigel invasion assay, western blot, ELISA | Expression of: | |
| • KIR2DL4 | ↓ | |||||
| • NKG2A | ↓ | |||||
|
| Prospective case control |
RIF (n = 32) vs controls (n = 23) | Endometrial tissue taken on Day 7–9 post-LH surge | IHC | Ratio of cells in endometrium: | |
| • CD57+: CD56+ ratio | ↑ | |||||
| Correlation between ratio of | ||||||
| • CD57+ to CD56+ and percentage of |
| |||||
| FoxP3+ in endometrium | RM and controls | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 49) vs Controls (n = 52) | Decidual samples at time of miscarriage/TOP | qRT-PCR; western blot; ELISA | Expression of: | |
| • miR30e | ↓ | |||||
|
| ||||||
|
| Prospective case control | 15 RM 15 controls | Endometrial tissue (RM); decidual tissue at TOP for (controls) | FC | Expression of | |
| • CD49a | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 8) vs controls (n = 45; | Decidual samples at time of miscarriage/TOP | FC | Expression of: | |
| • CD82 | ↓ | |||||
| • CD29 | ↑ | |||||
| on CD56dim | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 58) vs controls (n = 49) | Endometrial tissue taken on in mid-luteal phase | IHC | Correlation of NK cells with: | |
| IDO | POSITIVE in | |||||
| RM and controls | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 39) vs controls (n = 63) | Endometrial samples | IHC | uNK correlation with: | |
| • FoxP3 Tregs | POSITIVE RM and controls | |||||
| • PGRMC1 | NEGATIVE RM | |||||
| POSITIVE controls | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 30) vs controls (n = 30) | Endometrial biopsy on day LH surge +7 | Multiplex IHC staining | Correlation of uNk cell density with: | |
| • CD3+ cell density | POSITIVE | |||||
Effect direction in relation to RM/RIF group: ↑increase; ↓decrease; ↔no difference between the groups.
P < 0.05.
ERPC, evacuation of retained products of conception; FC, flow cytometry; IHC, immunohistochemistry; RIF, recurrent implantation failure; RM, recurrent miscarriage; STOP, surgical termination of pregnancy; TOP, termination of pregnancy; uRM, unexplained recurrent miscarriage.
Uterine NK cell activity by effect on uterine vasculature.
| Author/year | Study design | Study groups and sample number | Tissue sampled | Method of analysis | Outcome measure | Direction of effect of in RM/RIF patients |
|---|---|---|---|---|---|---|
|
| Prospective case control |
RIF (n = 35) vs controls (n = 12) | Endometrial tissue at luteal phase, either on Day 20 under oestrogen–progesterone replacement or Day 6 post-urinary LH surge | IHC; USS | No clear correlation between cytokine staining/depletion of IL-12 and IL-18, number of NK cells and ultrasound Doppler in RIF or controls | Qualitative analysis |
|
| ||||||
|
| Prospective case control |
RIF (n = 37) vs controls (n = 8) | Endometrial tissue at luteal phase, either on Day 21 under oestrogen–progesterone replacement | IHC; USS; qRT-PCR | • Mean UA PI | ↑ |
| • Mean number of NK cells | ↑ | |||||
| • Mean ET | ↓ | |||||
| • Endometrial (IL-12; IL-15; IL-18) cytokine mRNA ratio | ↔ | |||||
|
| ||||||
|
| Prospective case control |
RIF (n = 40) vs Controls (n = 8) | Endometrial tissue D7-9 post-LH surge | IHC, rtPCR, USS | • Sub-endometrial flow | |
| • Uterine artery pulsatility | ||||||
| Correlation of cytokine mRNA ratio: | ||||||
| with sub-endometrial flow and CD56+ count | ||||||
| • IL-15 |
| |||||
| With mean UA PI | ||||||
| • IL-15 | ||||||
| • IL-18 | ||||||
| • IL-18BP |
| |||||
|
| ||||||
|
| Prospective case control |
RIF (n = 26) vs controls (n = 18) | Endometrial tissue on Day 5–9 after ovulation (by ultrasound) | FC; ELISA | Correlation of CD16+ uNK with endometrial cell culture supernatant protein expression: | |
| • IL-6 (n = 28) |
| |||||
| • VEGF (n = 31) | RIF and controls | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 40) vs controls (n = 30) | Decidual samples at time of miscarriage/TOP between 6 and 10 weeks gestation | IHC; TEM | Non-remodelling score |
|
| RM and controls | ||||||
|
| ||||||
|
| Prospective case control |
15 RM (n = 14) controls (n = 7) | Endometrial tissue taken on in mid-luteal phase Day 7–9 post-ovulation | IHC; western blot; qRT-PCR | Correlation of CD56+ cell count with: | |
| • VSMC expressing SMM | ↔ | |||||
| • CD31+ endothelial cells | ↔ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 18) vs controls (n = 10) | Endometrial samples on Day 7 post-LH surge. | Angiogenic array; ELISA | Expression of: | |
| • angiogenin |
| |||||
| • bFGF | ||||||
| • VEGF-A | ||||||
Effect direction in relation to RM/RIF group: ↑increase;↓decrease; ↔no difference between the groups.
P < 0.05.
bFGF, basic fibroblast growth factor; ET, endometridal thickness; IHC, immunohistochemistry; IL-18BP, Interleukin-18 binding protein; qRT-PCR, real-time quantitative PCR; RIF, current implantation failure; RM, recurrent miscarriage; SMM, smooth muscle myosin; TEM, transmission electron microscopy; TOP, termination of pregnancy; UA PI, uterine artery pulsatility index; USS, ultrasound scan; VSMC, vascular smooth muscle cells.
Uterine NK cell activity by cytotoxicity.
| Author/year | Study design | Study groups and sample number | Tissue sampled | Method of analysis | Outcome measure | Direction of effect of cytotoxicity In RM/RIF patients |
|---|---|---|---|---|---|---|
|
| Prospective case control |
RM (n = 10) vs controls (n = 21) | Decidual tissue at time of miscarriage/STOP | Cr release assay | Lytic activity20 | ↑ |
|
| ||||||
|
| Prospective case control | RM (n = 32) vs controls (n = 35) | Decidual samples at time of miscarriage/STOP | LDH release assay | % lysed K562 cells | ↑ |
|
| ||||||
|
| Prospective case control |
RM (n = 13) vs Controls (n = 10) | Endometrial tissue on Day 7–9 post-LH surge | IHC | Expression of | |
| • % NKp46: endometrial stroma | ↑ | |||||
| • Ratio NKp46: CD56+ | ↑ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 26) vs controls (n = 37) | Decidual samples at time of miscarriage/TOP | FC; PCR | Intracellular | |
| • Granzyme | ↑ | |||||
| mRNA expression | ||||||
| • GrB | ↑ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 28) RIF (n = 34) Controls (n = 74) | Endometrial tissue taken on Day 7–9 post-LH surge | FC: | • NKp44, NKp30 | ↔ RM, RIF or controls |
| • NK p46+ expression | ↓ | |||||
| on CD56; CD56bright and CD56dim | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 3) vs controls (n = 3) | Decidual samples at time of miscarriage/STOP | Cr release assay | % lysed K562 cells | ↑ |
|
| ||||||
|
| Prospective case control |
RM (n = 15) vs Controls (n = 15) | Decidual samples at time of miscarriage/STOP | FC | Protein expression | |
| • Perforin |
| |||||
| • GzmB | ||||||
| mRNA expression | ||||||
| • PRF1 |
| |||||
| • GzmB | ||||||
Effect direction in relation to RM/RIF group: ↑increase; ↓decrease; ↔no difference between the groups.
P < 0.05; confidence of the effect estimate has been determined by application of the binomial test.
Cr, chromium; FC, flow cytometry; GzmB, Granzyme B; IHC, immunohistochemistry; LDH, lactate dehydrogenase; RIF, recurrent implantation failure; RM, recurrent miscarriage; STOP, surgical termination of pregnancy.
Uterine NK cell activity by cytokine expression.
| Author/year | Study design | Study groups and sample number | Tissue sampled | Method of analysis | Outcome measure, e.g. cytokine | Direction of effect in RM/RIF patients |
|---|---|---|---|---|---|---|
|
| Prospective case control |
71 uRM (n = 71) vs patients and STOP for healthy controls (n = 20) | Decidual samples at ERPC (uRM patients) and STOP for healthy controls (all <12/40) | IHC |
30% of women with RM demonstrated increased NK cell infiltrates in maternal decidua at the implantation site. No correlation between increased CD57+ NK cell infiltrates at the implantation site with (i) inadequate cytotrophoblast depth of invasion (ii) inadequate number of intermediate trophoblast | Qualitative analysis |
|
| ||||||
|
| Prospective case control |
RM (n = 25) vs controls (n = 285) | Decidual samples at time of miscarriage/TOP | FC; ELISA | • IL-1RA | ↓ |
| • IL-10 |
| |||||
| • IFN-γ | ↓ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 26) vs controls (n = 37) | Decidual samples at time of miscarriage/TOP | FC; PCR | Intracellular | |
| • IFN-γ | ↑ | |||||
| mRNA expression | ||||||
| • IFN-γ | ↑ | |||||
|
| ||||||
|
| Prospective case control |
28 RM 34 RIF 74 controls | Mid-luteal endometrium | FC | TNF-α and IFN-γ expression | |
| • RM | ↓ | |||||
| • RIF | ↓ | |||||
| on CD56, CD56bright and CD56dim | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 20) vs controls (n = 20) | Decidual samples at time of miscarriage/TOP | FC | dNK cytokine ratio expression using FSC/SSC gating strategy | |
| dNK1/dNK2 ratio | ↑ | |||||
|
| ||||||
| dNK2 = IFNγ-IL4+ | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 11) vs controls (n = 12) included in study n = 6 in both groups for cytokine expression assays | Decidual samples at time of miscarriage/TOP | FC, RT-PCR, Matrigel invasion assay, western blot, ELISA | Expression of cytokines in purified CD94+CD56+CD16− dNK: | |
| IL-8 | ↓ | |||||
| • IP-10 | ↓ | |||||
| • VEGF | ↓ | |||||
| • IFN-γ | ↑ | |||||
|
| ||||||
|
| Prospective case control |
RM (n = 10) with normal chromosomes vs controls (n = 21) | Decidual samples at time of miscarriage/TOP between 6 and 10 weeks gestation | FC | Cytokine expression | |
| • TNF-α (dNK1) | ↑ | |||||
| • IL-4 (dNK2) | ↓ | |||||
| • dNK1: dNK2 ratio | ↑ | |||||
| on CD3−CD56brightCD16− cells | ||||||
|
| ||||||
|
| Prospective case control |
RM (n = 15) vs controls (n = 15) | Decidual tissue at ERPC/TOP between 7 and 10 weeks | FC | mRNA expression • PRF1 • IFN-γ |
|
|
| Prospective case control |
RM (n = 26) vs controls (n = 60) | Decidual samples at time of miscarriage/TOP between 6-10 weeks gestation | FC; real-time PCR | Cytokine protein expression | |
| • IFN-γ | ↑ | |||||
| • TNF-α | ↑ | |||||
| • IL-4 | ↓ | |||||
| • IL-10 | ↔ | |||||
| Cytokine mRNA expression | ||||||
| • IFN-γ | ↑ | |||||
| • TNF-α | ↑ | |||||
| • IL-4 | ↓ | |||||
| • IL-10 | ↔ | |||||
Effect direction in relation to RM/RIF group: ↑increase; ↓decrease; ↔no difference between the groups.
P < 0.05.
ERPC, evacuation of retained products of conception; FC, flow cytometry; FSC, forward scatter; IFN-γ, Interferon-γ; IHC, immunohistochemistry; IP-10, interferon gamma-induced protein 10; RIF, recurrent implantation failure; RM, recurrent miscarriage; SC, side scatter; STOP, surgical termination of pregnancy; TNF-α, tumour necrosis factor-α; TOP, termination of pregnancy; VEGF, vascular endothelial growth factor; uRM, unexplained recurrent miscarriage.